Exactus, Inc.: management transactions · United States · SEC (Form 4)

About Exactus, Inc.

Exactus, Inc. (ticker: EXDI) is a United States-listed company with a highly transitional corporate history and a profile that should be viewed through the lens of a small-cap, event-driven equity rather than a mature operating franchise. The company was incorporated in 2008 in Nevada as an alternative energy R&D business, later shifted toward point-of-care diagnostics, and then expanded into hemp- and cannabidiol (CBD)-related activities in 2019. SEC filings also show that Exactus has undergone multiple corporate and operational pivots, including changes in name, address, and strategic focus over time. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1552189/000165495417002846/exdi10k_dec312016.htm?utm_source=openai)) Historically, Exactus pursued the development of portable diagnostic solutions, including a product concept called FibriLyzer, described in SEC filings as a handheld point-of-care platform intended to deliver rapid results through a disposable biosensor strip. That earlier strategy positioned the company in a niche medical diagnostics segment aimed at acute care and cardiovascular applications. The company later broadened its business scope toward industrial hemp and CBD products, reflecting a shift from medtech ambitions to cannabinoid commercialization. In its 2022 SEC reporting, Exactus disclosed that it had acquired Panacea Life Sciences in 2021, which effectively transformed the business into a seed-to-sale cannabinoid company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1552189/000165495417002846/exdi10k_dec312016.htm?utm_source=openai)) From a competitive standpoint, Exactus does not appear to operate as a scale leader in either diagnostics or cannabinoids. Instead, its market relevance comes from its strategic optionality, restructuring activity, and the visibility created by SEC reporting, including Form 4 insider transaction filings. For investors, this means the investment case is less about dominant products or a broad geographic footprint and more about whether management can execute a credible operating model in a crowded and regulated environment. The available public record suggests a company in flux, with business-model evolution taking precedence over stable, recurring fundamentals. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001552189/000149315222008215/form10-k.htm?utm_source=openai)) For SEO and investor-reference purposes, it is important to state clearly that Exactus is a United States company associated with the American public markets, and that its history includes periods of trading and filing activity under the EXDI symbol. Because the company has changed direction several times, the most relevant recent “news” is not a single product launch but rather the ongoing evidence from SEC filings that the business remains in a restructuring and repositioning phase. Investors should therefore treat the name as a highly speculative microcap with limited disclosure depth compared with larger NYSE/NASDAQ issuers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1552189/000165495417002846/exdi10k_dec312016.htm?utm_source=openai))